(Q35118750)

6 August 2017

1 reference

title

Novel strategies for the treatment of sepsis (English)

1 reference

6 August 2017

0 references

3

Peter A Ward

1 reference

6 August 2017

Ren-Feng Guo

2

1 reference

6 August 2017

Niels C. Riedemann

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12724763

29 December 2023

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

http://www.nature.com/articles/nm0503-517.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/NM0503-517

http://www.nature.com/articles/nm0503-517

29 December 2023

1 reference

https://api.crossref.org/works/10.1038/NM0503-517

29 December 2023

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

517-524

1 reference

https://scigraph.springernature.com/pub.10.1038/nm0503-517

6 August 2017

exact match

0 references

cites work

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Medical responsibility in orthetics

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Steroid controversy in sepsis and septic shock: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Cytokines IL-1beta, IL-6, and TNF-alpha enhance in vitro growth of bacteria

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Shock and tissue injury induced by recombinant human cachectin

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Interleukin-1 receptor antagonist reduces mortality from endotoxin shock

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

A new approach in the treatment of hypotension in human septic shock by NG-monomethyl-L-arginine, an inhibitor of the nitric oxide synthetase.

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

L-arginine pathway in the sepsis syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

New and emerging therapies for sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Immunotherapy of sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Clinical trials of immunomodulatory therapies in severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Risks and benefits of activated protein C treatment for severe sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Activation of endothelial cell protease activated receptor 1 by the protein C pathway

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

HMGB1 as a late mediator of lethal systemic inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

HMG-1 as a late mediator of endotoxin lethality in mice

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis.

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

MIF as a glucocorticoid-induced modulator of cytokine production

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Protection from septic shock by neutralization of macrophage migration inhibitory factor

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

MIF regulates innate immune responses through modulation of Toll-like receptor 4

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculaturein vitro andin vivo

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

C5a receptor and thymocyte apoptosis in sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Role of C5a in multiorgan failure during sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Protective effects of C5a blockade in sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Increased C5a receptor expression in sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Complement-induced impairment of innate immunity during sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

The chemotactic receptor for human C5a anaphylatoxin

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Apoptosis in sepsis: a new target for therapeutic exploration

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Prevention of lymphocyte cell death in sepsis improves survival in mice

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis

1 reference

https://api.crossref.org/works/10.1038%2FNM0503-517

7 January 2021

Identifiers

DOI

10.1038/NM0503-517

1 reference

Dimensions Publication ID

6 August 2017

1043719642

0 references

1 reference